Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

406

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

October 11, 2026

Study Completion Date

October 11, 2026

Conditions

IBS (Irritable Bowel Syndrome)IBS-D (Diarrhea-predominant)IBS, Mixed Symptoms

Interventions

DRUG

Saccharomyces Boulardii 250 MG

Saccharomyces boulardii CNCM I-745, 250 mg, 2 capsules/day

DRUG

Placebo 250 mg

Placebo, 250mg, 2 capsules/day